Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+memory cytotoxic T lymphocytes (CTL). Results will be presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at 8 a.m. CDT, and noon CDT, respectively, Saturday, June 4, 2011, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The study is the first to demonstrate the combined immunologic and clinical effects of AGS-003, or any active immunotherapy, with sunitinib. Most patients experienced reversal of baseline tumor-induced immunosuppression and showed improved progression-free survival (PFS) compared to the expected PFS with sunitinib alone in an unfavorable risk, metastatic RCC patient population. Assessment of immunodynamicsusing multiparametric flow cytometry was performed on peripheral blood mononuclear cells isolated from blood draws collected prior to treatment and after treatment with AGS-003 during combination administration with sunitinib. Nine of 11 patients with PFS of >10 months demonstrated CTL population increases whereas two of four patients with PFS <10 months showed increases in this specific CTL population. Updates on the correlation between prolonged PFS and CTL expansion will be presented during ASCO.

"The study provides initial evidence that AGS-003
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Corporation (Nasdaq: IRIX ) today reported financial results ... , Revenues were $11.8 million in the fourth ... 11% from $10.6 million in the 2013 fourth quarter. Revenues ... from $38.3 million in 2013. , Gross margin for ... the fourth quarter of the prior year. , Operating ...
(Date:3/5/2015)... SEATTLE and TÜBINGEN, Germany ... Bill & Melinda Gates Foundation and CureVac today ... to invest $52 million (€46 million) in CureVac, ... vaccine technologies. As part of the agreement, the ... projects to develop prophylactic vaccines based on CureVac,s ...
(Date:3/5/2015)...  BioPhotas, Inc., an FDA registered medical device manufacturer ... to treat skin, muscle and joint conditions, today announced ... to provide BioPhotas, flagship product, the Celluma, ... Commenting on the alliance, Patrick ... Celluma at the Warrior Hope and Care Center had ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3
(Date:3/5/2015)... New York, NY (PRWEB) March 05, 2015 ... first time in more than a decade. She has hinted ... not want to miss seeing her perform one last time. ... two years and this beloved country sweetheart has millions of loyal ... be touring throughout her native country, Canada, and on June 30th ...
(Date:3/5/2015)... Risperdal lawsuits ( http://www.risperdallawsuit2014.com/ ) ... tort litigation currently underway in the Philadelphia Court ... hearing testimony in the proceeding’s second bellwether trial ... cause gynecomastia, or male breast growth. According to ... on behalf of a plaintiff who was prescribed ...
(Date:3/5/2015)... HomeCEUConnection.com is proud to support ... on their nutrition CEUs. To raise awareness ... HomeCEUConnection.com is offering 10% off selected nutrition ... NUTRITION2015 . , High Quality Continuing Education ... high-quality continuing education courses for Physical Therapists, ...
(Date:3/5/2015)... In honor of National Drug Facts ... drug and alcohol abuse in schools and communities across ... with information on some of the dangers and statistics ... National Institute on Drug Abuse, this annual promotion of ... the illusions that teens and young adults get from ...
(Date:3/5/2015)... March 05, 2015 Califia Farms ... announced at Natural Products Expo West that its popular ... 100 percent soy and dairy free. Califia Farms Vegan ... bottle and are packed with six grams of an ... includes fiber, B vitamins and magnesium. , Protein is ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3
... HealthDay Reporter , WEDNESDAY, Nov. 9 (HealthDay News) ... new research finds that it may also increase levels of ... At this point, though, it,s not entirely clear what the ... appears online Nov. 9 in the American Journal of ...
... HealthDay Reporter , WEDNESDAY, Nov. 9 (HealthDay News) ... in the blood appears to help obese rhesus monkeys lose ... approach may help obese humans lose weight, according to the ... blood vessels of white fat tissue is a novel conceptual ...
... have been collaborating with Pitt,s School of Medicine to find ... part to a four-year, $1.86 million grant from the National ... the National Institutes of Health (NIH). The NSF grant began ... within Pitt,s Department of Mathematics; the NIH grant is in ...
... 9 issue of the Journal of Neuroscience, ... of Medicine and University of Washington describe in deeper ... also reveal new cellular targets for possibly slowing its ... inherited neurological disorder in which cells in the cerebellum ...
... of childhood asthma should extend beyond the doctor,s ... spend most of their time dealing with the ... studies. A key to successful implementation of childhood ... community-based care coordination approach that combines evidence-based science, ...
... FRANCISCO -- Progress in oncology drug development will take ... and industry experts convene at the Moscone Center West ... Targets and Cancer Therapeutics. "During the last few ... result of tremendous developments in the understanding of the ...
Cached Medicine News:Health News:New Research Questions Wisdom of Cutting Down on Salt 2Health News:Experimental Drug Slims Obese Monkeys 2Health News:Experimental Drug Slims Obese Monkeys 3Health News:Pitt researchers using mathematics to target Parkinson's disease symptoms 2Health News:Neurological disorder impacts brain cells differently 2Health News:Community-based care coordination effective for real world asthma management programs 2Health News:Community-based care coordination effective for real world asthma management programs 3Health News:AACR-NCI-EORTC to hold molecular targets meeting in San Francisco 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: